- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation | ||
| Fr | FDA says it's hiring more than 1,000 new staffers, launches new comms program for review process | ||
| Do | Moderna's reshaping rolls on with 3 more pipeline purges | ||
| Do | Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3 | ||
| Do | Ensoma halves workforce after transitioning genetic medicine to the clinic | ||
| Do | Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach | ||
| Do | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| Mi | Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO | ||
| Mi | Celltrion still thinking bigger than biosimilars with option for $350M antibody deal | ||
| Mi | Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir | ||
| Mi | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| Mi | GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space | ||
| Di | How Biogen is returning to its roots with a West Coast immunology outpost | ||
| Di | Vanda tackles Wegovy-driven vomiting, sparking race to phase 3 | ||
| Di | Jefferies' London conference cements reputation as 'JP Morgan for Europe' | ||
| Di | Roche's oral SERD goes 2 for 2, hitting goal in phase 3 adjuvant breast cancer trial | ||
| Mo | Genmab sheds another clinical ADC from $1.8B ProfoundBio buy | ||
| Mo | Repare finds fix as biotech agrees to XenoTherapeutics buyout | ||
| Mo | Bayer opens Beijing incubator and names initial occupants, tightening ties to China | ||
| Mo | J&J buys into Halda cell death tech with $3B acquisition, beefing up prostate cancer pipeline | ||
| Mo | Nxera lays off 15% of staff, pivots pipeline focus in profitability push | ||
| Mo | Nuvalent shares lung cancer data, sparking race to FDA for would-be Pfizer rival | ||
| 14.11. | Sensei shrinks workforce by 65%, terminates 3 executive roles | ||
| 14.11. | Merck pays $9.2B for Cidara, picking up flu antiviral spurned by J&J | ||
| 14.11. | BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .